Sarepta Therapeutics (SRPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 464,450 | 801,282 | 613,077 | 510,598 | 240,867 |
| Marketable Securities | 188,739 | 138,368 | 237,916 | 289,541 | 281,895 |
| Receivables | 394,817 | 398,233 | 395,739 | 527,295 | 659,371 |
| Inventories | 1,001,112 | 914,744 | 1,077,166 | 994,036 | 941,432 |
| Other current assets | 260,758 | 285,311 | 398,411 | 335,515 | 308,968 |
| TOTAL | $2,309,876 | $2,537,938 | $2,722,309 | $2,656,985 | $2,432,533 |
| Non-Current Assets | |||||
| PPE Net | 336,241 | 345,125 | 358,936 | 371,857 | 360,587 |
| Investments And Advances | 81,936 | 1,048 | 1,040 | 230,126 | 263,495 |
| Other Non-Current Assets | 450,881 | 465,592 | 411,152 | 420,846 | 408,772 |
| TOTAL | $869,058 | $811,765 | $771,128 | $1,022,829 | $1,032,854 |
| Total Assets | $3,178,934 | $3,349,703 | $3,493,437 | $3,679,814 | $3,465,387 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 70,376 | 280,841 | 94,015 | 136,702 | 156,105 |
| Accrued Expenses | 302,372 | 359,659 | 295,793 | 377,399 | 391,650 |
| Other current liabilities | 10,379 | 11,393 | 46,168 | 10,416 | 12,974 |
| TOTAL | $499,164 | $1,095,290 | $921,425 | $919,948 | $605,588 |
| Non-Current Liabilities | |||||
| Long Term Debt | 838,162 | 828,974 | 1,035,146 | 1,139,458 | 1,138,289 |
| Deferred Revenues | 116,037 | 443,397 | 485,449 | 395,431 | 44,859 |
| Other Non-Current Liabilities | 200,152 | 200,907 | 216,746 | 263,023 | 253,787 |
| TOTAL | $1,174,668 | $1,113,791 | $1,251,892 | $1,402,481 | $1,717,076 |
| Total Liabilities | $1,673,832 | $2,209,081 | $2,173,317 | $2,322,429 | $2,322,664 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 105,576 | 104,990 | 104,787 | 97,713 | 98,277 |
| Common Shares | 11 | 11 | 11 | 10 | 10 |
| Retained earnings | -4,546,025 | -4,876,984 | -4,641,537 | -4,461,590 | -4,658,482 |
| Other shareholders' equity | -384 | 9 | -43 | -314 | 34 |
| TOTAL | $1,505,102 | $1,140,622 | $1,320,120 | $1,357,385 | $1,142,723 |
| Total Liabilities And Equity | $3,178,934 | $3,349,703 | $3,493,437 | $3,679,814 | $3,465,387 |